Docon Sells 9.9% Stake in Thyrocare for Rs 986 Crore
Docon Technologies divests nearly 10% of Thyrocare, dropping its stake to 51.02%.
Docon Technologies, a significant promoter of Thyrocare Technologies Ltd, has offloaded a 9.9% stake in the diagnostics firm, generating Rs 986 crore through various transactions executed on August 14, 2026. This strategic move involved the sale of 1,57,69,696 equity shares across both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
Breakdown of the Transaction
The sale was structured through a combination of bulk and block deals, with more than 1.31 crore shares sold via block deals. Additionally, 10 lakh shares were traded through bulk deals on the NSE, and another 16.01 lakh shares were exchanged on the BSE. The shares were priced between Rs 624 and Rs 631.71 each, culminating in a total transaction value of Rs 985.86 crore.
Following this sale, Docon's holding in Thyrocare decreased from 60.92% to 51.02%. This marks a continuation of Docon's sell-off strategy, following a similar transaction last October where a 10% stake was sold for Rs 667 crore.
Investor Participation
The stake sale attracted significant interest from institutional investors, insurance companies, and global investment entities. Notable participants included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance companies such as Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance were also involved, alongside international players like Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.
Market Reaction
In the wake of the transaction, Thyrocare Technologies' shares experienced a modest increase. On the NSE, shares rose nearly 3% to Rs 621.95, while on the BSE, they climbed over 2% to Rs 622. The precise identities of other investors involved in the bulk deals remain undisclosed.
This substantial stake sale reflects Docon's ongoing strategy to recalibrate its investment in Thyrocare, while the reception from prominent financial entities underscores the enduring appeal of the diagnostics sector in India.